View Author
patient myeloma thalidomide response study treatment regimen therapy university analysis blood cancer factor trial number bortezomib hospital survival group hovon dexamethasone table month combination result -50 erasmus mc myeloma sk kumar thrombosis lenalidomide outcome pathway diagnosis figure response rates institute disease transplant stage center fi rst regimen hematology association kumar level event-free survival effect clinic mayo clinic apoptosi leukemia mrc myeloma ix br j haematol validation cytokine thalidomide-related criteria prognostic factors speci sample control erasmu j thromb haemost thalidomide exposure identi prognostic .999 myeloma cells research venou duration library 2011. tissue factor mechanism december volume aspirin france dataset
2 Most Recent Publications
|
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
(Article)
Kumar, S. Lee, J.H. Leleu, X. Hulin, C. Klein, S.K. Sonneveld, P. Siegel, D. Bladé, J. Goldschmidt, H. Jagannath, S. Miguel, J.S. Orlowski, R.Z. Lahuerta, J.J. Palumbo, A. Sezer, O. Rajkumar, S.V. Durie, B.G.M. Morgan, G. Richardson, P.G. Crowley, J. Haessler, J. Feather, J. Hoering, A. Moreau, P. |
2012-01-01
|
|
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
(Article)
Johnson, D.C. Corthals, S.L. Jackson, G. Baris, D. Rajkumar, S.V. Davies, F. Durie, B.G.M. Crowley, J. Sonneveld, P. Ness, B. van Morgan, G. Ramos, C. Hoering, A. Cocks, K. Dickens, N.J. Haessler, J. Goldschmidt, H. Child, J.A. Bell, S.E. |
2008-12-15
|
